pegylated-interferon
Recombinant proteinexperimental
Clinical trial activity
20 trials · 27 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
14
Phase 3
5
Phase 4
3
Earliest trial started Sep 1, 2003 (NCT00219739)
Timeline
Indications
Approved for
Studied for
- Health · Phase 2
- Hepatitis B · Phase 2
- Hepatitis B, Chronic · Phase 4
- Hepatitis C · Phase 2
- Hepatitis C, Chronic · Phase 4
- HIV · Phase 4
- HIV Infections · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 3
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Liver Diseases · Phase 1/Phase 2
- Quality of Health Care · Phase 2
- Thrombocythemia, Essential · Phase 2/Phase 3
Mechanism of action
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- peg-ifn
- pegylated interferon
- pegylated-interferon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07135349 | Phase 2 | Sep 2, 2025 | Government of China |
| NCT07069569 | Phase 2 | May 30, 2025 | Capital Medical University, Government of China |
| NCT06923280 | N/A | May 1, 2025 | Fudan University |
| NCT05133856 | Phase 2 | Dec 31, 2021 | Jiao Tong University, Shanghai HEP Pharmaceatical Co., Ltd. |
| NCT04676724 | Phase 2 | Jan 28, 2021 | GlaxoSmithKline |
| NCT04426968 | Phase 2 | Aug 31, 2020 | People's Liberation Army of China, Shanghai HEP Pharmaceatical Co., Ltd. |
| NCT03357822 | Phase 4 | Jan 25, 2018 | Huazhong University of Science and Technology |
| NCT02962388 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2017 | French Innovative Leukemia Organisation, Novartis |
| NCT02767193 | Phase 1 | May 1, 2016 | University of Barcelona |
| NCT02637999 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Hepatera Ltd., Moscow Regional Resarch adn Clinical Institute |
| NCT02060058 | Phase 3 | Nov 1, 2013 | Kaohsiung Medical University, National Taiwan University |
| NCT01743521 | Phase 4 | Jan 1, 2013 | Johnson and Johnson, University of New South Wales |
| NCT01725204 | Phase 2 | Sep 1, 2012 | Norwegian University of Science and Technology |
| NCT01655966 | Phase 3 | May 1, 2012 | Cairo University |
| NCT01220596 | Phase 3 | Jun 1, 2010 | Hanyang University, Roche |
| NCT00704184 | Phase 2 | Jul 1, 2008 | Merck |
| NCT00979706 | Phase 4 | Mar 1, 2005 | University of Barcelona |
| NCT01227356 | Phase 2 | Sep 1, 2004 | Karolinska Institute, Uppsala University |
| NCT00085917 | Phase 2 | Jun 1, 2004 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00219739 | Phase 3 | Sep 1, 2003 | Government of France, Novartis, Roche, University of Poitiers |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 1 | 2025 |
| Novartis | For profit | 2 | 0 | 1 | 2003 |
| Roche | For profit | 2 | 0 | 1 | 2003 |
| Shanghai HEP Pharmaceatical Co., Ltd. | For profit | 2 | 2 | 1 | 2020 |
| University of Barcelona | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| French Innovative Leukemia Organisation | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2021 |
| Government of France | Government | 1 | 0 | 1 | 2003 |
| Hanyang University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Hepatera Ltd. | For profit | 1 | 1 | 1 | 2014 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2013 |
| Kaohsiung Medical University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Merck | For profit | 1 | 1 | 1 | 2008 |
| Moscow Regional Resarch adn Clinical Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |
27 organizations
Page 1 / 2